0001104659-18-006230.txt : 20180202
0001104659-18-006230.hdr.sgml : 20180202
20180202160805
ACCESSION NUMBER: 0001104659-18-006230
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180131
FILED AS OF DATE: 20180202
DATE AS OF CHANGE: 20180202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gelone Steven P.
CENTRAL INDEX KEY: 0001693064
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 18570729
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
a4.xml
4
X0306
4
2018-01-31
0
0001641640
Nabriva Therapeutics plc
NBRV
0001693064
Gelone Steven P.
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
0
1
0
0
Chief Scientific Officer
Stock Options
2018-01-31
4
A
0
100000
0.00
A
2028-01-31
Ordinary Shares
100000
100000
D
Restricted Stock Units
2018-01-31
4
A
0
22500
0.00
A
2021-01-31
Ordinary Shares
22500
22500
D
The exercise price is $6.47 per share.
The option award was granted on January 31, 2018. Vesting began on January 31, 2018 and ends on January 31, 2022. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units.
Vesting of the restricted stock unit award is subject to U.S. Food and Drug Administration ("FDA") approval of a new drug application ("NDA") for lefamulin. Fifty percent (50%) of the restricted stock unit award will vest upon FDA approval of an NDA for lefamulin, and the remaining fifty percent (50%) of the restricted stock unit award will vest on the one (1) year anniversary of such approval. If the FDA does not approve an NDA for lefamulin within two years of the grant date, the the restricted stock unit award will terminate in full.
/s/ Robert Crotty, by power of attorney
2018-02-02